Intellia Therapeutics (NASDAQ:NTLA) Shares Up 4.8%


Share on StockTwits

Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s stock price shot up 4.8% during trading on Thursday . The stock traded as high as $75.27 and last traded at $74.52. 1,819 shares traded hands during trading, a decline of 100% from the average session volume of 1,703,067 shares. The stock had previously closed at $71.09.

Several research firms have recently commented on NTLA. Robert W. Baird downgraded shares of Intellia Therapeutics from an “outperform” rating to a “neutral” rating and set a $60.00 price objective for the company. in a research note on Tuesday, December 22nd. Truist lifted their price objective on shares of Intellia Therapeutics from $40.00 to $80.00 in a research note on Friday, February 26th. Barclays lifted their price objective on shares of Intellia Therapeutics from $46.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, January 8th. Zacks Investment Research upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 3rd. Finally, JMP Securities assumed coverage on shares of Intellia Therapeutics in a research note on Wednesday, March 10th. They set an “outperform” rating and a $80.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $56.85.

The business’s fifty day simple moving average is $65.65 and its two-hundred day simple moving average is $50.92. The company has a market cap of $4.92 billion, a PE ratio of -31.18 and a beta of 2.09.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.12). Intellia Therapeutics had a negative net margin of 193.01% and a negative return on equity of 40.14%. As a group, analysts forecast that Intellia Therapeutics, Inc. will post -2.27 EPS for the current fiscal year.

In other news, EVP Jose E. Rivera sold 54,659 shares of the business’s stock in a transaction dated Monday, February 1st. The shares were sold at an average price of $63.99, for a total transaction of $3,497,629.41. Following the transaction, the executive vice president now owns 120,068 shares of the company’s stock, valued at approximately $7,683,151.32. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Jose E. Rivera sold 11,489 shares of the business’s stock in a transaction dated Tuesday, February 9th. The shares were sold at an average price of $75.00, for a total transaction of $861,675.00. Following the transaction, the executive vice president now directly owns 129,409 shares in the company, valued at approximately $9,705,675. The disclosure for this sale can be found here. Insiders sold 892,987 shares of company stock valued at $58,204,964 in the last ninety days. 4.10% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the company. Retirement Group LLC acquired a new position in shares of Intellia Therapeutics during the 4th quarter valued at about $27,000. Perigon Wealth Management LLC purchased a new stake in Intellia Therapeutics in the 4th quarter valued at about $28,000. Sowell Financial Services LLC raised its holdings in Intellia Therapeutics by 147.3% in the 4th quarter. Sowell Financial Services LLC now owns 544 shares of the company’s stock valued at $30,000 after buying an additional 324 shares during the period. Carroll Financial Associates Inc. purchased a new stake in Intellia Therapeutics in the 1st quarter valued at about $34,000. Finally, BNC Wealth Management LLC purchased a new stake in Intellia Therapeutics in the 3rd quarter valued at about $72,000. 95.58% of the stock is currently owned by hedge funds and other institutional investors.

About Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

Read More: Different Options Trading Strategies

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.